Myelodysplastic Syndromes (MDS) Clinical Trials in Bologna
3 recruitingBologna, Italy
Showing 1–3 of 3 trials
Recruiting
Phase 3
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Myelodysplastic Syndromes (MDS)Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
Institut de Recherches Internationales Servier48 enrolled62 locationsNCT06465953
Recruiting
Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Myelodysplastic Syndromes (MDS)
Celgene665 enrolled143 locationsNCT04064060
Recruiting
Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome
Myelodysplastic Syndromes (MDS)
IRCCS Azienda Ospedaliero-Universitaria di Bologna60 enrolled1 locationNCT06764511